Novartis muscle wasting drug gets 'breakthrough' status
ZURICH (Reuters) - Novartis said on Tuesday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM).
The U.S. Food and Drug Administration (FDA) created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.
sIBM is a rare yet potentially life-threatening muscle-wasting condition. Patients suffering from the disease can gradually lose the ability to walk. There are currently no approved treatments, according to Novartis.
Bimagrumab was developed by Novartis in collaboration with Morphosys. The drug works by stimulating muscle growth by blocking from inhibitory molecules.
(This corrects day of the week to Tuesday from Thursday)
(Reporting by Caroline Copley)
- Mexican train derails, stranding 1,300 migrants headed toward U.S.
- Gaza toll nears 100, Israel to counter rockets 'with all power' |
- Texas mass murder suspect collapses in court as crime recounted
- Ukraine says rebels will pay as missiles kill 23 soldiers |
- British 'Harry Potter' actor David Legeno found dead in U.S. park
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video